
Merck Tops Revenue Estimates at $18.1 Billion; Adjusted EPS Beats at $2.49
Merck raised the midpoint of its full-year sales outlook to $66.8 billion to $67.3 billion and narrowed its adjusted EPS guidance to $2.77 to $2.82, including a one-time $0.12-per-share charge tied to a SciBrunch license.